<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349722</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2019-521</org_study_id>
    <nct_id>NCT04349722</nct_id>
  </id_info>
  <brief_title>The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae</brief_title>
  <official_title>A Randomised Control Study: The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the duration of active phase of labour in women who received buscopan and
      those who don't.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised control study involving primigravida in labour who require pitocin augmentation.
      Once patient require augmentation, patient will be randomised into intervention group
      (receiving intravenous buscopan 1ml or 20mg) and control group (intravenous normal saline
      1ml). Both fluids are colourless. The primary outcome is duration from augmentation to os
      fully. The secondary outcome are to look on mode of delivery particularly any caesarean
      section due to failure to poor progress, maternal side effect (dry mouth and tachycardia) and
      baby outcome (apgar score and neonatal intensive care unit admission)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparison between participants who receive hyoscine and those who do not.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Participants and care provider are blinded from the treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Labor length</measure>
    <time_frame>Through study completion until delivery up to 12 hours</time_frame>
    <description>Duration of labor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal age</measure>
    <time_frame>At the time of recruitment</time_frame>
    <description>Mean maternal age in years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age</measure>
    <time_frame>At the time of recruitment</time_frame>
    <description>Mean gestational age in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-pregnancy body mass index</measure>
    <time_frame>At the time of recruitment</time_frame>
    <description>Mean body mass index in kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First stage of labor</measure>
    <time_frame>From onset of regular contraction to cervical dilatation of 10 cm up to 24 hours</time_frame>
    <description>Mean duration of first stage of labor in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second stage of labour</measure>
    <time_frame>From cervical dilatation of 10cm until delivery of fetus</time_frame>
    <description>Mean duration of second stage of labour in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Third stage of labour</measure>
    <time_frame>From delivery of fetus until delivery of placenta</time_frame>
    <description>Mean duration of third stage of labour in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Through study completion up to 42 days after delivery</time_frame>
    <description>Mean blood loss in millilitres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>Through study completion up to 12 hours</time_frame>
    <description>Percentage of participants who delivered vaginally or via caesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia</measure>
    <time_frame>Through study completion until delivery up to 12 hours</time_frame>
    <description>Percentage of women need analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Pre-intervention</time_frame>
    <description>Mean pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score 2 hours</measure>
    <time_frame>From time of intervention up to 2 hours after</time_frame>
    <description>Mean pain score at 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score 4 hours</measure>
    <time_frame>From time of intervention up to 4 hours after</time_frame>
    <description>Mean pain score at 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score 6 hours</measure>
    <time_frame>From time of intervention up to 6 hours after</time_frame>
    <description>Mean pain score at 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcome 1 minute</measure>
    <time_frame>From delivery of neonate up to 1 minute after</time_frame>
    <description>Mean apgar score at 1 minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcome 5 minute</measure>
    <time_frame>From delivery of neonate up to 5 minutes after</time_frame>
    <description>Mean apgar score at 1 minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit admission</measure>
    <time_frame>From delivery of neonate up to 30 days</time_frame>
    <description>Percentage of neonates require admission to neonatal intensive care unit admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Through study completion up to 42 days after delivery</time_frame>
    <description>Percentage of participants who develop side effects to treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Labor Long</condition>
  <arm_group>
    <arm_group_label>Hyoscine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive intravenous bolus of 1ml (20 mg) Hyoscine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive intravenous bolus of 1ml normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyoscine Butylbromide</intervention_name>
    <description>Intervention is given once a participant is in established labor</description>
    <arm_group_label>Hyoscine</arm_group_label>
    <other_name>Buscopan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention is given once a participant is in established labor</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primigravida

          -  Vertex presentation

          -  Term gestation (37-41w)

          -  Active phase of labor (4cm with regular contraction at least 2:10)

          -  Spontaneous labor

          -  Oxytocin augmentation

          -  Maternal height â‰¥150cm

        Exclusion Criteria:

          -  Multiple pregnancies

          -  Previous uterine surgery

          -  Hypertensive disease in pregnancy

          -  Gestational diabetes on treatment

          -  Clinical estimation of fetal weight &gt;3.8kg

          -  Induction of labor

          -  Meconium stained liquor

          -  Allergy to hyoscine

          -  Medical contraindication to hyoscine (i.e Myasthenia gravis, glaucoma, megacolon)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aida Hani Mohd Kalok</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rahana Abd Rahman</last_name>
    <phone>+60122719985</phone>
    <email>drrahana@ppukm.ukm.edu.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aida Hani Mohd Kalok</last_name>
    <email>aida.kalok@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National University Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jemaima Che Hamzah</last_name>
      <email>jemaima@ppukm.ukm.edu.my</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Rahana Abd Rahman</investigator_full_name>
    <investigator_title>Co-primary investigator</investigator_title>
  </responsible_party>
  <keyword>hyoscine</keyword>
  <keyword>Duration of labour</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

